Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ADA | P00813 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ASPH | Q12797 | 1/20 | 0.34 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.34 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4040582 | 0.89 | KIT (0.39) | NR3C2OPRM1OPRK1OPRD1ANPEP | |
| SCHEMBL4045617 | 0.78 | ADRB1 (0.36) | OPRM1OPRK1OPRD1ANPEPERAP2 | |
| SCHEMBL4036513 | 0.78 | RPS6KB1 (0.40) | ADRB2ADRB1ADRB3KCNH2KDM4E | |
| SCHEMBL4041765 | 0.77 | ADRB3 (0.46) | ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL4044662 | 0.76 | ABCB1 (0.39) | OPRM1ANPEPERAP2ADRB2ADRB1 | |
| SCHEMBL4037688 | 0.74 | KDM4E (0.46) | OPRM1OPRK1OPRD1ANPEPERAP2 | |
| SCHEMBL7157672 | 0.74 | CYP1A2 (0.56) | ADRB2ADRB1KDM4E | |
| SCHEMBL4042381 | 0.73 | ADRB2 (0.59) | OPRM1ADRB2ADRB1ADRB3 | |
| SCHEMBL4049170 | 0.72 | MPO (0.39) | OPRM1ADRB2ADRB1ADRB3KCNH2 | |
| SCHEMBL4985396 | 0.71 | MMP1 (0.45) | NR3C2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-7148215-B2 | Prodrugs as antihistamines or anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | AVENTIS PHARMA S.A, (FR) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | NR3C2 574/4885OPRM1 2514/4885OPRK1 1008/4885 |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | CNKSR1, ROS1, NRAS | NR3C2 411/4885OPRM1 1162/4885OPRK1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.